Selecting the optimal antithrombotic regimen for patients with acute coronary syndromes undergoing percutaneous coronary intervention

References

• Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre studyFRagmin and Fast Revascularisation during InStability in Coronary artery disease InvestigatorsLancet1999354918070871510475181
   PubMedGoogle Scholar
• SabatineMSMorrowDAGiuglianoRPImplications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trialCirculation2004109787488014757697
   PubMed Web of Science ®Google Scholar
• FoxKAPoole-WilsonPAHendersonRAInterventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Randomized Intervention Trial of unstable AnginaLancet2002360933574375112241831
   PubMed Web of Science ®Google Scholar
• NeumannFJKastratiAPogatsa-MurrayGEvaluation of prolonged antithrombotic pretreatment (“cooling-off ” strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trialJAMA2003290121593159914506118
   PubMed Web of Science ®Google Scholar
• KeeleyECBouraJAGrinesCLPrimary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trialsLancet20033619351132012517460
   PubMed Web of Science ®Google Scholar
• Lloyd-JonesDAdamsRCarnethonMHeart disease and stroke statistics – 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics SubcommitteeCirculation20091193e21e18119075105
   PubMed Web of Science ®Google Scholar
• FuchsSKornowskiRTeplitskyIMajor bleeding complicating contemporary primary percutaneous coronary interventions-incidence, predictors, and prognostic implicationsCardiovasc Revasc Med2009102889319327670
   PubMedGoogle Scholar
• KinnairdTDStabileEMintzGSIncidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventionsAm J Cardiol200392893093514556868
   PubMed Web of Science ®Google Scholar
• DoyleBJRihalCSGastineauDAHolmesDRJrBleeding, blood transfusion, and increased mortality after percutaneous coronary intervention: implications for contemporary practiceJ Am Coll Cardiol200953222019202719477350
   PubMed Web of Science ®Google Scholar
• KingSB3rdSmithSCJrHirshfeldJWJr2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelinesJ Am Coll Cardiol200851217220918191745
   PubMed Web of Science ®Google Scholar
• FalkEShahPKFusterVCoronary plaque disruptionCirculation19959236576717634481
   PubMed Web of Science ®Google Scholar
• FusterVMorenoPRFayadZACortiRBadimonJJAtherothrombosis and high-risk plaque: part I: evolving conceptsJ Am Coll Cardiol200546693795416168274
   PubMed Web of Science ®Google Scholar
• Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patientsBMJ20023247329718611786451
   PubMed Web of Science ®Google Scholar
• CairnsJAGentMSingerJAspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trialN Engl J Med198531322136913753903504
   PubMed Web of Science ®Google Scholar
• LewisHDJrDavisJWArchibaldDGProtective effects of aspirin against acute myocardial infarction and death in men with unstable angina Results of a Veterans Administration Cooperative StudyN Engl J Med198330973964036135989
   PubMed Web of Science ®Google Scholar
• WallentinLCAspirin (75 mg/day) after an episode of unstable coronary artery disease: long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. Research Group on Instability in Coronary Artery Disease in Southeast SwedenJ Am Coll Cardiol1991187158715931960301
   PubMed Web of Science ®Google Scholar
• FosterCJProsserDMAgansJMMolecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugsJ Clin Invest2001107121591159811413167
   PubMed Web of Science ®Google Scholar
• QuinnMJFitzgeraldDJTiclopidine and clopidogrelCirculation1999100151667167210517740
   PubMed Web of Science ®Google Scholar
• HaushoferAHalbmayerWMPracharHNeutropenia with ticlopidine plus aspirinLancet199734990504744759040584
   PubMed Web of Science ®Google Scholar
• BennettCLWeinbergPDRozenberg-Ben-DrorKYarnoldPRKwaanHCGreenDThrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 casesAnn Intern Med199812875415449518398
   PubMed Web of Science ®Google Scholar
• WiviottSDTrenkDFrelingerALPrasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trialCirculation2007116252923293218056526
   PubMed Web of Science ®Google Scholar
• WiviottSDBraunwaldEMcCabeCHPrasugrel versus clopidogrel in patients with acute coronary syndromesN Engl J Med2007357202001201517982182
   PubMed Web of Science ®Google Scholar
• BerkowitzSDCurrent knowledge of the platelet glycoprotein IIb/IIIa receptor antagonists for the treatment of coronary artery diseaseHaemostasis200030Suppl 3274311182626
   PubMedGoogle Scholar
• HirshJAnandSSHalperinJLFusterVGuide to anticoagulant therapy: Heparin: a statement for healthcare professionals from the American Heart AssociationCirculation2001103242994301811413093
   PubMed Web of Science ®Google Scholar
• MelandriGSempriniFCerviVComparison of efficacy of low molecular weight heparin (parnaparin) with that of unfractionated heparin in the presence of activated platelets in healthy subjectsAm J Cardiol19937254504548394644
   PubMed Web of Science ®Google Scholar
• ShantsilaELipGYChongBHHeparin-induced thrombocytopenia. A contemporary clinical approach to diagnosis and managementChest200913561651166419497901
   PubMed Web of Science ®Google Scholar
• MelloniCAlexanderKPChenAYUnfractionated heparin dosing and risk of major bleeding in non-ST-segment elevation acute coronary syndromesAm Heart J2008156220921518657648
   PubMed Web of Science ®Google Scholar
• BahitMCTopolEJCaliffRMReactivation of ischemic events in acute coronary syndromes: results from GUSTO-IIb. Gobal Use of Strategies To Open occluded arteries in acute coronary syndromesJ Am Coll Cardiol20013741001100711263599
   PubMed Web of Science ®Google Scholar
• GoodmanSGBarrASobtchoukALow molecular weight heparin decreases rebound ischemia in unstable angina or non-Q-wave myocardial infarction: the Canadian ESSENCE ST segment monitoring substudyJ Am Coll Cardiol20003651507151311079650
   PubMed Web of Science ®Google Scholar
• TherouxPWatersDLamJJuneauMMcCansJReactivation of unstable angina after the discontinuation of heparinN Engl J Med199232731411451608405
   PubMed Web of Science ®Google Scholar
• WarkentinTELevineMNHirshJHeparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparinN Engl J Med199533220133013357715641
   PubMed Web of Science ®Google Scholar
• Schmidt-LuckeCSchultheissHPEnoxaparin injection for the treatment of high-risk patients with non-ST elevation acute coronary syndromeVasc Health Risk Manag20073222122817580732
   PubMedGoogle Scholar
• AroraUKDhirMDirect thrombin inhibitors (part 1 of 2)J Invasive Cardiol2005171343815640538
   PubMedGoogle Scholar
• AroraUKDhirMDirect thrombin inhibitors (part 2 of 2)J Invasive Cardiol2005172859115687531
   PubMedGoogle Scholar
• A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigatorsN Engl J Med1996335117757828778585
   PubMed Web of Science ®Google Scholar
• Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) InvestigatorsLancet199935391514294389989712
   PubMedGoogle Scholar
• AndersonJLAdamsCDAntmanEMACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency MedicineCirculation20071167e148e30417679616
   PubMed Web of Science ®Google Scholar
• YusufSMehtaSRChrolaviciusSComparison of fondaparinux and enoxaparin in acute coronary syndromesN Engl J Med2006354141464147616537663
   PubMed Web of Science ®Google Scholar
• SchulmanSBijsterveldNRAnticoagulants and their reversalTransfus Med Rev2007211374817174219
   PubMed Web of Science ®Google Scholar
• CrowtherMABerryLRMonaglePTChanAKMechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparinBr J Haematol2002116117818611841415
   PubMed Web of Science ®Google Scholar
• BijsterveldNRMoonsAHBoekholdtSMAbility of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteersCirculation2002106202550255412427650
   PubMed Web of Science ®Google Scholar
• CrowtherMAWarkentinTEBleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agentsBlood2008111104871487918309033
   PubMed Web of Science ®Google Scholar
• BertrandMERupprechtHJUrbanPGershlickAHDouble-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS)Circulation2000102662462910931801
   PubMed Web of Science ®Google Scholar
• MullerCButtnerHJPetersenJRoskammHA randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stentsCirculation2000101659059310673248
   PubMed Web of Science ®Google Scholar
• TaniuchiMKurzHILasalaJMRandomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient populationCirculation2001104553954311479250
   PubMed Web of Science ®Google Scholar
• GentMBlakelyJAEastonJDThe Canadian American Ticlopidine Study (CATS) in thromboembolic strokeLancet198918649121512202566778
   PubMed Web of Science ®Google Scholar
• YusufSZhaoFMehtaSRChrolaviciusSTognoniGFoxKKEffects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevationN Engl J Med2001345749450211519503
   PubMed Web of Science ®Google Scholar
• MehtaSRYusufSPetersRJEffects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE studyLancet2001358928152753311520521
   PubMed Web of Science ®Google Scholar
• SteinhublSRBergerPBMannJT3rdEarly and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trialJAMA2002288192411242012435254
   PubMed Web of Science ®Google Scholar
• EbrahimiRDykeCMehranROutcomes following pre-operative clopidogrel administration in patients with acute coronary syndromes undergoing coronary artery bypass surgery: the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trialJ Am Coll Cardiol200953211965197219460609
   PubMed Web of Science ®Google Scholar
• GurbelPABlidenKPHiattBLO’ConnorCMClopidogrel for coronary stenting: response variability, drug resistance, and the effect of pre-treatment platelet reactivityCirculation2003107232908291312796140
   PubMed Web of Science ®Google Scholar
• CuissetTFrereCQuiliciJBenefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stentingJ Am Coll Cardiol20064871339134517010792
   PubMed Web of Science ®Google Scholar
• YongGRankinJFergusonLRandomized trial comparing 600- with 300-mg loading dose of clopidogrel in patients with non-ST elevation acute coronary syndrome undergoing percutaneous coronary intervention: results of the Platelet Responsiveness to Aspirin and Clopidogrel and Troponin Increment after Coronary intervention in Acute coronary Lesions (PRACTICAL) TrialAm Heart J2009157160 e61e6919081397
   PubMed Web of Science ®Google Scholar
• PattiGColonnaGPasceriVPepeLLMontinaroADi SciascioGRandomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) studyCirculation2005111162099210615750189
   PubMed Web of Science ®Google Scholar
• MontalescotGWiviottSDBraunwaldEPrasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trialLancet2009373966572373119249633
   PubMed Web of Science ®Google Scholar
• WiviottSDBraunwaldEMcCabeCHIntensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trialLancet200837196211353136318377975
   PubMed Web of Science ®Google Scholar
• Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC InvestigationN Engl J Med1994330149569618121459
   PubMed Web of Science ®Google Scholar
• Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG InvestigatorsN Engl J Med199733624168916969182212
   PubMed Web of Science ®Google Scholar
• Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockadeLancet1998352912287929672272
   PubMed Web of Science ®Google Scholar
• BrenerSJBarrLABurchenalJERandomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) InvestigatorsCirculation19989887347419727542
   PubMed Web of Science ®Google Scholar
• MontalescotGBarraganPWittenbergOPlatelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarctionN Engl J Med2001344251895190311419426
   PubMed Web of Science ®Google Scholar
• NeumannFJKastratiASchmittCEffect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarctionJ Am Coll Cardiol200035491592110732888
   PubMed Web of Science ®Google Scholar
• Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosisCirculation1997965144514539315530
   PubMed Web of Science ®Google Scholar
• van’t HofAWErnstNde BoerMJFacilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trialEur Heart J2004251083784615140531
   PubMed Web of Science ®Google Scholar
• Van’t HofAWTen BergJHeestermansTPrehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trialLancet2008372963853754618707985
   PubMed Web of Science ®Google Scholar
• Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-IILancet19973499063142214289164315
   PubMed Web of Science ®Google Scholar
• Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trialLancet200035692472037204411145489
   PubMed Web of Science ®Google Scholar
• HorwitzPABerlinJASauerWHLaskeyWKKroneRJKimmelSEBleeding risk of platelet glycoprotein IIb/IIIa receptor antagonists in broad-based practice (results from the Society for Cardiac Angiography and Interventions Registry)Am J Cardiol200391780380612667564
   PubMed Web of Science ®Google Scholar
• BoersmaEHarringtonRAMoliternoDJPlatelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trialsLancet2002359930218919811812552
   PubMed Web of Science ®Google Scholar
• TopolEJMoliternoDJHerrmannHCComparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularizationN Engl J Med2001344251888189411419425
   PubMed Web of Science ®Google Scholar
• ValgimigliMCampoGPercocoGComparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trialJAMA2008299151788179918375998
   PubMed Web of Science ®Google Scholar
• De LucaGUcciGCassettiEMarinoPBenefits from small molecule administration as compared with abciximab among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-analysisJ Am Coll Cardiol200953181668167319406342
   PubMed Web of Science ®Google Scholar
• KastratiAMehilliJNeumannFJAbciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trialJAMA2006295131531153816533938
   PubMed Web of Science ®Google Scholar
• RasoulSOttervangerJPde BoerMJA comparison of dual vs triple antiplatelet therapy in patients with non-ST-segment elevation acute coronary syndrome: results of the ELISA-2 trialEur Heart J200627121401140716682384
   PubMed Web of Science ®Google Scholar
• GiuglianoRPWhiteJABodeCEarly versus delayed, provisional eptifibatide in acute coronary syndromesN Engl J Med2009360212176219019332455
   PubMed Web of Science ®Google Scholar
• MehilliJKastratiASchulzSAbciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trialCirculation2009119141933194019332467
   PubMed Web of Science ®Google Scholar
• FungAYSawJStarovoytovAAbbreviated infusion of eptifibatide after successful coronary intervention The BRIEF-PCI (Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention) randomized trialJ Am Coll Cardiol2009531083784519264239
   PubMed Web of Science ®Google Scholar
• BertrandOFDe LarochelliereRRodes-CabauJA randomized study comparing same-day home discharge and abciximab bolus only to overnight hospitalization and abciximab bolus and infusion after transradial coronary stent implantationCirculation2006114242636264317145988
   PubMed Web of Science ®Google Scholar
• MarmurJDMitreCABarnathanECavusogluEBenefit of bolus-only platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: insights from the very early outcomes in the Evaluation of 7E3 for the Prevention of Ischemic Complications (EPIC) trialAm Heart J2006152587688117070148
   PubMed Web of Science ®Google Scholar
• MarmurJDPoludasuSAgarwalAManjappaNCavusogluEHigh-dose tirofiban administered as bolus-only during percutaneous coronary interventionJ Invasive Cardiol2008202535818252967
   PubMed Web of Science ®Google Scholar
• MarmurJDPoludasuSAgarwalABolus-only platelet glycoprotein IIb-IIIa inhibition during percutaneous coronary interventionJ Invasive Cardiol2006181152152617090813
   PubMedGoogle Scholar
• MarmurJDPoludasuSLazarJCavusogluELong-term mortality after bolus-only administration of abciximab, eptifibatide, or tirofiban during percutaneous coronary interventionCatheter Cardiovasc Interv200973221422119156882
   PubMed Web of Science ®Google Scholar
• TherouxPOuimetHMcCansJAspirin, heparin, or both to treat acute unstable anginaN Engl J Med198831917110511113050522
   PubMed Web of Science ®Google Scholar
• OlerAWhooleyMAOlerJGradyDAdding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysisJAMA1996276108118158769591
   PubMed Web of Science ®Google Scholar
• CohenMDemersCGurfinkelEPA comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study GroupN Engl J Med199733774474529250846
   PubMed Web of Science ®Google Scholar
• AntmanEMMcCabeCHGurfinkelEPEnoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trialCirculation1999100151593160110517729
   PubMed Web of Science ®Google Scholar
• AntmanEMCohenMRadleyDAssessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysisCirculation1999100151602160810517730
   PubMed Web of Science ®Google Scholar
• FergusonJJCaliffRMAntmanEMEnoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trialJAMA20042921455415238590
   PubMed Web of Science ®Google Scholar
• de LemosJABlazingMAWiviottSDEnoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the A phase of the A-to-Z trialEur Heart J200425191688169415451146
   PubMed Web of Science ®Google Scholar
• EikelboomJWAnandSSMalmbergKWeitzJIGinsbergJSYusufSUnfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysisLancet200035592191936194210859038
   PubMed Web of Science ®Google Scholar
• PetersenJLMahaffeyKWHasselbladVEfficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overviewJAMA20042921899615238596
   PubMed Web of Science ®Google Scholar
• BassandJPHammCWArdissinoDGuidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromesEur Heart J200728131598166017569677
   PubMed Web of Science ®Google Scholar
• ColletJPMontalescotGLisonLPercutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectorisCirculation2001103565866311156876
   PubMed Web of Science ®Google Scholar
• DenardoSJDavisKETchengJEEffectiveness and safety of reduced-dose enoxaparin in non-ST-segment elevation acute coronary syndrome followed by antiplatelet therapy alone for percutaneous coronary interventionAm J Cardiol200710091376138217950793
   PubMed Web of Science ®Google Scholar
• ClarkNPLow-molecular-weight heparin use in the obese, elderly, and in renal insufficiencyThromb Res2008123Suppl 1S58S6118809206
   PubMed Web of Science ®Google Scholar
• LimWDentaliFEikelboomJWCrowtherMAMeta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiencyAnn Intern Med2006144967368416670137
   PubMed Web of Science ®Google Scholar
• NutescuEASpinlerSAWittkowskyADagerWELow-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settingsAnn Pharmacother20094361064108319458109
   PubMed Web of Science ®Google Scholar
• AntmanEMHandMArmstrongPW2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice GuidelinesJ Am Coll Cardiol200851221024718191746
   PubMed Web of Science ®Google Scholar
• BittlJAStronyJBrinkerJATreatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study InvestigatorsN Engl J Med1995333127647697643883
   PubMed Web of Science ®Google Scholar
• LincoffAMKleimanNSKottke-MarchantKBivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET)Am Heart J2002143584785312040347
   PubMed Web of Science ®Google Scholar
• GibsonCMMorrowDAMurphySAA randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trialJ Am Coll Cardiol200647122364237316781360
   PubMed Web of Science ®Google Scholar
• StoneGWMcLaurinBTCoxDABivalirudin for patients with acute coronary syndromesN Engl J Med2006355212203221617124018
   PubMed Web of Science ®Google Scholar
• WhiteHDOhmanEMLincoffAMSafety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trialJ Am Coll Cardiol2008521080781418755342
   PubMed Web of Science ®Google Scholar
• WhiteHDChewDPHoekstraJWSafety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trialJ Am Coll Cardiol200851181734174118452778
   PubMedGoogle Scholar
• StoneGWWitzenbichlerBGuagliumiGBivalirudin during primary PCI in acute myocardial infarctionN Engl J Med2008358212218223018499566
   PubMed Web of Science ®Google Scholar
• LincoffAMSteinhublSRManoukianSVInfluence of Timing of Clopidogrel Treatment on the Efficacy and Safety of Bivalirudin in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention An Analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) TrialJACC Cardiovasc Interv20081663964819463378
   PubMed Web of Science ®Google Scholar
• KastratiANeumannFJMehilliJBivalirudin versus unfractionated heparin during percutaneous coronary interventionN Engl J Med2008359768869618703471
   PubMed Web of Science ®Google Scholar
• LincoffAMBittlJAHarringtonRABivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trialJAMA2003289785386312588269
   PubMed Web of Science ®Google Scholar
• HillisLDLangeRAOptimal management of acute coronary syndromesN Engl J Med2009360212237224019458369
   PubMed Web of Science ®Google Scholar
• AntmanEMCohenMBerninkPJThe TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision makingJAMA2000284783584210938172
   PubMed Web of Science ®Google Scholar
• EagleKALimMJDabbousOHA validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registryJAMA2004291222727273315187054
   PubMed Web of Science ®Google Scholar
• BoersmaEPieperKSSteyerbergEWPredictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT InvestigatorsCirculation2000101222557256710840005
   PubMed Web of Science ®Google Scholar
• SubherwalSBachRGChenAYBaseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding ScoreCirculation2009119141873188219332461
   PubMed Web of Science ®Google Scholar
• LopesRDAlexanderKPManoukianSVAdvanced age, anti-thrombotic strategy, and bleeding in non-ST-segment elevation acute coronary syndromes: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trialJ Am Coll Cardiol200953121021103019298914
   PubMedGoogle Scholar
• DiezJGCohenMBalancing myocardial ischemic and bleeding risks in patients with non-ST-segment elevation myocardial infarctionAm J Cardiol2009103101396140219427435
   PubMed Web of Science ®Google Scholar
• ZikriaJCAnsellJOral anticoagulation with factor Xa and thrombin inhibitors: on the threshold of changeCurr Opin Hematol2009
   PubMed Web of Science ®Google Scholar
• MegaJLBraunwaldEMohanaveluSRivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trialLancet20093749683293819539361
   PubMed Web of Science ®Google Scholar
• AlexanderJHBeckerRCBhattDLApixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trialCirculation2009119222877288519470889
   PubMed Web of Science ®Google Scholar
• SteffelJLuscherTFNovel anticoagulants in clinical development: focus on factor Xa and direct thrombin inhibitorsJ Cardiovasc Med (Hagerstown)200910861662319561526
   PubMed Web of Science ®Google Scholar